ArticleFrontiers in pharmacology2021
Impact of the Pilot Volume-Based Drug Purchasing Policy in China: Interrupted Time-Series Analysis with Controls.
Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy of melatonin on drug- or contrast-induced acute kidney injury: a systematic review and GRADE-assessed meta-analysis of experimental and clinical studies.International urology and nephrology · 2025Pooled it
- Cost-effectiveness analysis of toripalimab and bevacizumab versus sorafenib for advanced hepatocellular carcinoma in China.Scientific reports · 2026Article
- Analysis of the impact of national centralized volume-based procurement drug policy on the market dynamics of tuberculosis drugs.BMC health services research · 2026Article
- From One-Size-Fits-All to Precision Medicine: The Promise of Personalized Probiotics.Probiotics and antimicrobial proteins · 2026Review
- The Contingent Payoff of Transparency: The Mediating Roles of Citizen Participation and Enforcement in Health Service Delivery Improvement.Journal of evaluation in clinical practice · 2026Review
- A study on the availability of national centralized drug procurement in regions with different levels of economic development: an investigation and analysis of 31 provincial-level administrative regions in China.Frontiers in pharmacology · 2026Article
- Impact of combined medication payment management policies on population health performance.PloS one · 2026Article
- Cost-effectiveness analysis of ibrutinib plus venetoclax for relapsed or refractory mantle cell lymphoma in China and the United States.Frontiers in public health · 2026Article
- Observational
- Impact of national volume-based procurement reform on the markup of pharmaceutical firms: an event study.Cost effectiveness and resource allocation : C/E · 2025Article
- Changes in antibiotic use associated with the National Centralized Drug Procurement policy in China from 2019 to 2023.Scientific reports · 2025Article
- Biogenesis and functional implications of extracellular vesicles in cancer metastasis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Review
- Exploring ferroptosis and miRNAs: implications for cancer modulation and therapy.Molecular and cellular biochemistry · 2025Review
- Natural sesquiterpene lactones in prostate cancer therapy: mechanisms and sources.Medical oncology (Northwood, London, England) · 2025Review
- Regulatory roles of non-coding RNAs in programmed cell death pathways and drug resistance in gastrointestinal stromal tumors.Clinical and experimental medicine · 2025Review
- Pharmacotherapeutic Strategies for Fine Particulate Matter-Induced Lung and Cardiovascular Damage: Marketed Drugs, Traditional Chinese Medicine, and Biological Agents.Cardiovascular toxicology · 2025Review
- Interpretation of coefficients in segmented regression for interrupted time series analyses.BMC medical research methodology · 2025Article
- Impact of national volume-based procurement policy on drugs treating chronic Myelogenous Leukemia.Journal of health, population, and nutrition · 2025Article
- Impact of China's National Volume-Based Drug Procurement: A Multilevel Interrupted Time Series Analysis on Medical Expenditures in Hypertensive Patients.International journal of health policy and management · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Centralizing procurement for prescription drugs has the potential to reduce drug spending by creating economies of scale and by improving purchasing power. In March 2019, the Chinese government launched a volume-based purchasing (VBP) pilot program using a competitive bidding process to purchase accredited generic drugs for which branded drug substitutes were available. We performed an interrupted time-series design to estimate the change in monthly drug purchase quantity and spending comparing 14 months before and 7 months after the VBP pilot. We obtained monthly prescription drug purchase data for all purchases from public medical institutions in the three large pilot cities (Beijing, Shanghai and Xi'an) and two non-pilot cities (Changsha and Zhengzhou) between January 2018 to September 2019. We used negative binomial regression and log-linked Gamma Generalized Linear Model for purchase quantity and spending respectively. We evaluated heterogeneity of impact by pilot city, drug type (selected or non-selected drugs), and therapeutic class (cardiovascular disease, mental disorder and cancer) separately. The implementation of the pilot reform was associated with a 132% (95%-CI: 104-165%,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.